Ulocuplumab clinical trials
Also written BMS-936564 and MDX-1338.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2010
How each study uses ulocuplumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2015 | 2 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 1
Studies
Open first, then newest update. How each study uses ulocuplumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's MacroglobulinemiaTerminatedPhase 1Dana-Farber Cancer InstituteNCT03225716Written as UlocuplumabHow we know
- An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid LeukemiaTerminatedPhase 1/2Bristol-Myers SquibbNCT02305563Written as BMS-936564How we know
- Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid TumorsTerminatedPhase 1/2Bristol-Myers SquibbNCT02472977Written as UlocuplumabHow we know
- First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell CancersCompletedPhase 1Bristol-Myers SquibbNCT01120457Written as BMS-936564 (Anti-CXCR4)How we know
Given beside what is tested · 1 — ulocuplumab is usual care or a partner of the new treatment
Codes
What other systems call ulocuplumab · ClinicalTrials.gg INT006306
- MeSH (NLM) C581980ulocuplumabOne source NLM
- UNII (FDA) 7KNP87L4X4ULOCUPLUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q21098907UlocuplumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C95755UlocuplumabOne source FDA
- DrugBank DB12018One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C581980 | ulocuplumab | One source NLM |
| UNII (FDA) | 7KNP87L4X4 | ULOCUPLUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q21098907 | Ulocuplumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C95755 | Ulocuplumab | One source FDA |
| DrugBank | DB12018 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.